CR20210021A - Apirasas solubilizadas, métodos y usos - Google Patents

Apirasas solubilizadas, métodos y usos

Info

Publication number
CR20210021A
CR20210021A CR20210021A CR20210021A CR20210021A CR 20210021 A CR20210021 A CR 20210021A CR 20210021 A CR20210021 A CR 20210021A CR 20210021 A CR20210021 A CR 20210021A CR 20210021 A CR20210021 A CR 20210021A
Authority
CR
Costa Rica
Prior art keywords
solubilized
methods
apirases
preventing
design
Prior art date
Application number
CR20210021A
Other languages
English (en)
Inventor
Boerje Haraldsson
Thomas Huber
Regina Link
Hilmar Ebersbach
Max Warncke
Agostino Cirillo
Chao Zou
Guido Junge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20210021A publication Critical patent/CR20210021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)

Abstract

<p>La invención se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados, composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.</p>
CR20210021A 2018-07-18 2019-07-17 Apirasas solubilizadas, métodos y usos CR20210021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18
PCT/IB2019/056117 WO2020016804A1 (en) 2018-07-18 2019-07-17 Solubilized apyrases, methods and use

Publications (1)

Publication Number Publication Date
CR20210021A true CR20210021A (es) 2021-03-23

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210021A CR20210021A (es) 2018-07-18 2019-07-17 Apirasas solubilizadas, métodos y usos

Country Status (27)

Country Link
US (2) US12325870B2 (es)
EP (1) EP3824079A1 (es)
JP (2) JP7425784B2 (es)
KR (1) KR102919646B1 (es)
CN (6) CN119020318A (es)
AR (1) AR115790A1 (es)
AU (1) AU2019306821B2 (es)
BR (1) BR112021000586A2 (es)
CA (1) CA3103684A1 (es)
CL (1) CL2021000129A1 (es)
CO (1) CO2021000210A2 (es)
CR (1) CR20210021A (es)
CU (1) CU24746B1 (es)
EA (1) EA202190057A1 (es)
EC (1) ECSP21002804A (es)
IL (1) IL280191A (es)
JO (1) JOP20210008A1 (es)
MA (1) MA53177A (es)
MX (1) MX2021000542A (es)
MY (1) MY203583A (es)
PE (1) PE20210185A1 (es)
PH (1) PH12021550122A1 (es)
SG (1) SG11202011776RA (es)
TW (1) TWI857965B (es)
UY (1) UY38299A (es)
WO (1) WO2020016804A1 (es)
ZA (1) ZA202007187B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (es) * 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
WO2021243173A1 (en) * 2020-05-28 2021-12-02 Charm Sciences, Inc. Methods and assemblies for sample analysis
CN119866373A (zh) 2022-07-29 2025-04-22 诺华股份有限公司 改善的cd39变体产生
TWI891029B (zh) * 2022-07-29 2025-07-21 瑞士商諾華公司 使用cd39、重組cd39用於急性器官損傷的治療
AU2024360371A1 (en) * 2023-10-13 2026-02-26 Danisco Usa Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
NZ511488A (en) * 1998-10-16 2003-10-31 Immunex Corp Inhibitors of platelet activation and recruitment comprising an Ala residue and heterologous peptides capable of forming a stable secondary structure attached to a CD39 polypeptide
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
US8551774B2 (en) 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
WO2008002157A1 (en) 2006-06-27 2008-01-03 Agresearch Limited Apyrases and uses thereof
US8535662B2 (en) * 2010-01-13 2013-09-17 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions
JP5913130B2 (ja) * 2010-01-13 2016-04-27 エイピーティー セラピューティックス，インク． 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法
SG11201604218RA (en) 2013-12-20 2016-07-28 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CA2934411C (en) 2013-12-20 2022-05-03 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos

Also Published As

Publication number Publication date
PH12021550122A1 (en) 2021-09-27
CN119020321A (zh) 2024-11-26
ZA202007187B (en) 2022-06-29
JOP20210008A1 (ar) 2021-01-12
US12325870B2 (en) 2025-06-10
ECSP21002804A (es) 2021-04-29
PE20210185A1 (es) 2021-02-02
AR115790A1 (es) 2021-02-24
SG11202011776RA (en) 2021-02-25
CN119020320A (zh) 2024-11-26
UY38299A (es) 2020-02-28
US20220356455A1 (en) 2022-11-10
CN119162148A (zh) 2024-12-20
AU2019306821B2 (en) 2022-09-29
IL280191A (en) 2021-03-01
JP7853263B2 (ja) 2026-04-28
TW202016299A (zh) 2020-05-01
EP3824079A1 (en) 2021-05-26
CN119020319A (zh) 2024-11-26
AU2019306821A1 (en) 2020-12-24
EA202190057A1 (ru) 2021-08-24
JP7425784B2 (ja) 2024-01-31
CN112424346A (zh) 2021-02-26
CL2021000129A1 (es) 2021-08-20
CA3103684A1 (en) 2020-01-23
CN119020318A (zh) 2024-11-26
MY203583A (en) 2024-07-05
KR102919646B1 (ko) 2026-01-29
TWI857965B (zh) 2024-10-11
US20250179447A1 (en) 2025-06-05
CN112424346B (zh) 2024-08-06
JP2024023297A (ja) 2024-02-21
WO2020016804A1 (en) 2020-01-23
CO2021000210A2 (es) 2021-01-18
CU20210008A7 (es) 2021-08-06
MA53177A (fr) 2021-05-26
CU24746B1 (es) 2025-04-04
JP2021529550A (ja) 2021-11-04
MX2021000542A (es) 2021-03-29
BR112021000586A2 (pt) 2021-04-06
KR20210035806A (ko) 2021-04-01

Similar Documents

Publication Publication Date Title
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
UY37831A (es) Nuevos derivados de quinolina
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
CL2016002389A1 (es) Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112012015386B8 (pt) composição oftálmica tópica
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX383386B (es) Nuevos inhibidores de braf y uso de los mismos para el tratamiento de reacciones cutáneas.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino